Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM-CX-2009: CX-2009 in Advanced Solid Tumors
NCT03149549Phase 2Terminated
- Sponsor
- CytomX
- Start
- Jun 2017
- Primary completion
- Sep 2020
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
Phase 2, open-label trial of praluzatamab ravtansine in solid tumor, breast cancer, non-small cell lung cancer (NSCLC) and 2 more (4 arms), sponsored by CytomX. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jun 2017; status: terminated.
02
Drugs
praluzatamab ravtansine
03
Conditions
solid tumorbreast cancernon-small cell lung cancer (NSCLC)head and neck cancer (HNC)ovarian cancer
Beyond the preview
Go deeper on NCT03149549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149549.